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Summary: This communication presents four different assay systems for the determination of myeloperoxidase
in body fluids. One is based on conventional chemiluminescence, two on luminescence-amplified enzyme
measurement using either spiroadamantane-1,2 dioxetanes with alkaline phosphatase or luminol/peroxidase/
4-iodophenol coupled with a peroxidase label.
The assays covered the range 0 — 600 μg/l peroxidase. Established reference range for EDTA plasma from
healthy volunteers gave an upper limit of 250 μg/l (95% confidence limits). Intra-assay coefficients of variation
were less than 5% for all assays, as seen in compound precision profiles. Inter-assay variation was less than
10% throughout the whole concentration range.
Kinetic curves for the light production were performed over a 2 hour period for the enhanced luminescence
assays. Dynamic ranges of these assays were compared with the conventional colorimetric assay using
4-nitrophenyl phosphate — alkaline phosphatase.
The assay was standardized using a commercially available myeloperoxidase preparation with defined enzy-
matic activity. The protein content was estimated and the laboratory standard compared and calibrated in
mass units.
Introduction _ _ - . r , , A -™sources (2, 3) and may therefore be used to differen-
Non-radioisotopically labelled immunoassays are be- tiate between various cellular reactions during pul-
coming increasingly important, especially those which monary insult, for example, during sepsis, protozoan,
are simple and robust, and attain the lower detection bacterial or viral attack (7, 9, 10).
limits of the radioimmunoassay or immunoradiome- ^ , .. , , . , . n „ t. -_- t r j-rv* · r · The assays described here are either with direct la-tnc assay. The results of different variants of immu- u ir „ , . , ., , , , « „ ,. · ι ι · t i - · belling where anti-myeloperoxidase has been labellednometnc assays with luminescent and colorimetric . - . . , „ . , t , „. „ _ ,, . j r u j 4.· r i Wlth a lummogen, or by universal labelling of thedetection are presented for the detection or myelo- - 1 1 - , - j ,1 . · -κτ ι. , - u j n - j x ^ r i - j - j same antibody with an amidocaproylbiotm-N-hy-peroxidase in body f l u i d s . Myeloperoxidase is used a s . . · · , T i t 1 1. . , . - ι. ι · ι droxysuccmimide ester. I n t h e latter case, t h e detec-a marker in diseases with granulocyte involvement . ^ . ^ Λ f ^ ^ ... , - n ,
/Λ . , ., „ τ . , , . tion system consisted οι streptavidm-labelled peroxi-(1—3) or in myeloid cell disorders (4 — 5), and its - „ ,. - - , - 1 . 1 ·- - ν. , dase or alkaline phosphatase together with a colon-measurement complements the assays for other gran- . t . · , , * / 4 4 „ 0 \, ι ι "c · /^ ox j metric or lummogenic substrate (11 —13).ulocyte components, namely lactofernn (6, 7) and
elastase-otrproteinase inhibitor complexes (7) devel- The luminogen used for direct coupling was 9-[N-(4
oped and published from this laboratory (7). Al- aminobutyl)-N-ethyl]-aminobenzo(f)phthalazine-l,4
though all three components usually correlate well (2H,3H) dione (ABEN). The luminescent substrate
with each other (8), they are secreted from different for alkaline phosphatase was 3-[(2'-spiroadaman-
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tane)-4-methoxy-4-(3'/phosphoryloxy)phenyl]-l,2
dioxetane (AMPPD), and the substrate for peroxidase
was hraiinol/peroxide with 4-iodophenol as enhancer.
An alkaline phosphatase-labelled enzyme immunoas-
say using 4-nitrophenyl phosphate as substrate was
performed for comparison.
The assays were tested under routine conditions,
which included the establishment of a reference range
for EDTA plasma from healthy volunteers (7), to-
gether with a comparison between myeloperoxidase,
lactoferrin and elastase- oci-proteinase inhibitor com-
plexes in cases of bronchial infection.
The luminescence-enhanced enzyme immunoassays
and the immunoenzymometric assay with colorimetric
measurement were based on microtitre plate technol-
ogy (14), whereas the chemiluminescent immunome-
tric assays used polystyrene balls as solid phase (15).
Materials and Methods
Materials
Myeloperoxidase was obtained as reference material from Beh-
ring-Calbiochem. (Marburg a. d. L., FRG) and was declared as
98% pure giving a single band after electrophoresis.
The myeloperoxidase used as standard in the assays was derived
from a pathological urine sample containing approximately 125
mg/1 myeloperoxidase. Dilutions were carried out in foetal calf
serum (Gibco, Paisley, GB).
Streptavidin was purchased from Boehringer Mannheim
(Mannheim, FRG) or from Biogenzia Lemania (Bochum,
FRG).
Streptavidin-peroxidase, anti-myeloperoxidase and streptavi-
din-alkaline phosphatase were bought from DAKO (Hamburg,
FRG).
AMPPD was purchased from Tropix Inc. (Bedford, MA. USA)
as a 10 g/1 solution.
ABEN was synthesised in the laboratories of the clinical re-
search unit of this hospital.
The luminol/peroxide and enhancer were commercial reagents
from Amersham International (Amerlite Signal Reagent),
Braunschweig FRG. Diethanolamine buffer (Art. Nr. 14000)
and 4-nitrophenyl phosphate (Art. Nr. 14001) were obtained in
ready to use form from Merck, Darmstadt, FRG.
Polystyrene balls (6.4 mm diameter) were purchased from
Spherotech Kugeln GmbH, Fulda, FRG.
Microtitre plates were obtained from Greiner, N rtingen, FRG,
and were γ-radiated. Both clear (Cat. No. 756061) and white
opaque plates (special lot — Cat. No. 701648) were used.
Other buffer substances were obtained from different sources.
Luminometers for reading 75 χ 12 mm tubes/cuvettes were
from Lab. Prof. Dr. Berthold (Type LB 952-16 T; 250-sample
chain-luminometer), Wildbad, FRG, or from Stratec (Type SL-
300; 300-sample rack-luminometer), Birkenfeld, FRG.
The microtitre plate luminometer (Luminoskan) was from ICN-
Flow Laboratories (Labsystems Oy), Helsinki, SF.
All machines were capable of performing data reduction with
integrated or connected microprocessors/desk top computers.
Methods
Immunometric assays were used throughout. Table 1 shows the
flow scheme for the assays based on polystyrene balls, table 2
for assays based on microtitre plates. The basic details of the
assays have been published several times for different compo-
nents elsewhere (7, 12) and need not be further dealt with here.
Tab. 1. Assay flow scheme for polystyrene ball-based immu-
nometric assays for myeloperoxidase using "direct-la-
belling" of the antibody.
20 μΐ sample or standard
200 μΐ ABEN-labelled anti myeloperoxidase (rabbit)
1 anti-myeloperoxidase coated ball (rabbit)
Incubate 45 min at ambient temperature on horizontal rotator
(170 min'1).
Wash with 2 χ 5 ml demineralized water.
Transfer balls to measuring cuvettes (Sarstedt 12 χ 75 mm —
No. 55.476).
Add 300 μΐ catalase (Boehringer Mannheim Cat. Nr. 106836
- 1:200 dilution in 0.15 mol/1 NaCl, 0.015 mol/1 NaN3,
pH5).
Load luminometer and initiate light reaction with alkaline per-
oxide (1 Perhydrit tablet (Merck Art. Nr. 7201) in 200 ml
0.33 mol/1 NaOH).
Integrate signal over 2 s and perform data reduction.
Tab. 2. Assay flow diagram for microtitre plate-based immu-
noassays for myeloperoxidase using "indirect" labelling
of the antibody with amidocaproylbiotin
20 μΐ sample or standard
200 μΐ biotinylated anti myeloperoxidase (rabbit)
1 anti-myeloperoxidase coated well (rabbit)
Incubate 45 min at 18 —25 °C on microtitre plate shaker. Wash
with 4 χ 250 μΐ 0.4 ml/1 Triton X-405 in demineralized water.
200 μΐ Streptavidin-labelled alkaline phosphatase for AMPPD
and 4-nitrophenyl phosphate as substrate (dilution 1 : 30 000)
200 μΐ Streptavidin-labelled peroxidase for luminol-peroxide 4-
iodophenol as substrate (dilution 1:20 000)
Incubate 30 minutes at 18 — 25 °C on microtitre plate shaker.
Wash as above.
200 μΐ AMPPD 0.4 mmol/1 in 0.1 mol/1 diethanolamine buffer
(Merck Art. Nr 14000 - ready to use), pH 9.8*
or
200 μΐ Amerlite signal reagent (contents not declared), pH 9.0*
or
200 μΐ 4-nitrophenyl phosphate (Merck Art. Nr. 14001) - 1
tablet in 15 ml 0.1 mol/1 diethanolamine buffer, pH 9.8*
For the luminescence measurement, load Luminoskan lumi-
nometer and scan plate (0.1 s/well) at time(s) required.
For the colorimetric determination stop reaction after 10 min
with 50 μΐ 0.25 mol/1 EDTA-Na4/NaOH, pH 13 and read in
microtitre plate colorimeter (Biorad El A reader 2550 or 3550)
at 405 nm.
* The substrate incubations were all carried out at ambient
temperature (18-25 °C)
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The assay buffer and throughout, unless otherwise specified,
was: 0.05 mol/1 phosphate, 0.15 mol/1 NaCl, 0.5 ml/1 Triton X-
405, pH 7.5. The substrates for the (luminescent-enhanced)
enzyme immuno-assays were used as follows:
a) AMPPD - 0.4 mmol/1 in 0.1 mol/1 diethanolamine buffer
b) 4-nitrophenyl phosphate — 1 tablet in 15 ml diethanolamine
buffer.
c) Luminol-peroxidase Signal Reagent Buffer (contents not
declared), pH 9.0
All substrate working solutions were prepared directly before
use and were discarded afterwards. Only AMPPD was stored
as a stock solution in the dark at 4 — 7 °C.
Stat is t ics
Non-parametric statistics were used throughout, after the Kol-
mogorov-Smirnoff lest showed non-normal distributions in sev-
eral data groups (a > 0.05). Correlations were made using the
Spearman rank test, graphical representations using the two
regression line technique — y = a + bx and χ = a 4- by. The
relevant percentiles and median values were used as locators.
Results and Discussion
Results
a) Polystyrene ball-based assays using ABEN as label
Figure 1 shows a typical standard curve for assays





Fig. 1. Standard curve (1-step assay) for myeloperoxidase using
ABEN-labelled anti-myeloperoxidase as the liquid
phase antibody. Assay details as in table 1. Reference
range for fresh EDTA plasma from healthy volunteers
up to 250 μg/l. The counts on the ordinate are arbitrary
and cannot be compared directly with those from the
microtitre plate luminometer.
b) Establishment of a reference range for plasma from
normal healthy volunteers
EDTA plasma was used throughout. The time be-
tween blood sampling and separation of plasma was
2 — 30 min (7). Haemolysed samples were discarded,
as were plasma samples from volunteers with elevated
aminotransferases, γ-glutamyl transferase, C-reactive
protein and neopterin. Table 3 shows 10 consecutive
assays using the assay described in table 1.
Tab. 3. Distribution of myeloperoxidase concentrations in 182
















Range of values 78-308 238-11290
Upper limit of the reference range for healthy volunteers in
fresh EDTA plasma was 250 μg/l (95% confidence limits)
c) Comparison of white blood cell constituents
Elastase-o^-proteinase inhibitor, lactoferrin and mye-
loperoxidase values in 49 patients with pulmonary
disease or infection using the assay in table 1 were
compared. The correlation between elastase-oci-pro-
teinase inhibitor and lactoferrin was 0.667, with mye-
loperoxidase 0.725. The correlation between lactofer-
rin and myeloperoxidase was 0.521. All correlation
coefficients were significant (p < 0.001 — Spearman
rank correlation). The distribution of myeloperoxi-
dase concentrations is given in table 3.
d) Inter- and intra-assay variations
Table 4 shows the basic data of the assays described
in section a) above in the form of compound precision
profiles for intra-assay variation, and conventionally
with mean values and coefficients of variation for
inter-assay comparison.
Tab. 4. Precision data for the polystyrene ball-based assay.
a. Compound precision profile
(data from duplicate determinations)
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e) Micro litre plate-based luminescence enhanced im-
munoenzymometric assays (LEIA) using an alka-
line phosphatase label
The luminescent substrate AMPPD is stable at pH
9.8. The substance is a dioxetane, which is a direct
precursor of molecules which luminesce, independent
of bio- or chemiluminescence. Through the action of
alkaline phosphatase, the AMPPD ~-anion yields a
constant light signal (11). Figure 2 shows the light
reaction kinetics in the form of a standard curve read
at 1, 5, 10, 60, 90 and 180 minutes after substrate was
pipetted into the microtitre plate wells. The light sig-
nal could be measured over 60 minutes without ap-
preciable loss of signal or loss in precision or dynamic





Fig. 2. Light kinetic curves over the first 3 hours for the
AMPPD-alkaline phosphatase system. Concentration
of AMPPD 0.4 mmol/1, pH 9.8. The counts on the
ordinate are arbitrary.
— # — l min 1 5 min ...···... 10 min
— χ — 30 min — O — 60 min —Χ— 180 min
f) Conventional immunoenzymometric assay using al-
kaline phosphatase 4-nitrophenyl phosphate
As a control system, 4-nitrophenyl phosphate in the
colorimetric determination replaced the AMPPD (see
(e)). The colour reaction was stopped after 10 minutes
with 50 μΐ of 0.25 mol/1 EDTA adjusted to pH 13
with solid NaOH. The colour was read at 405 nm.
Colourless microtitre plates replaced the opaque ones
used in (e) above.
g) Peroxidase system using luminoljper oxide 4-iodo-
phenol
The combination of peroxidase with luminol and per-
oxide has been known for over a decade (13) and is
used with success commercially. The light signal can
be "enhanced" (amplified) by using phenolic deriva-
tives such as 4-iodophenol.
The light signal is also stable as shown in figure 3.
The assay can be measured up to 30 minutes after
substrate addition. The reagents used here were ex-
actly as supplied by Amersham International in their





Fig. 3. Light kinetic curves for the peroxidase- luminol/perox-
ide system over a 2 hour time period with a reaction
pH of 9.0.
— * — l min 1 10 min ....··..- 20 min
— π— 30 min — χ — 120 min
h) Dynamic ranges of microtitre plate assays
Figure 4 shows standard curves for the two lumi-
nescence-enhanced enzyme immunoassays as well as
for the assay with colorimetric detection. All three
assays were set up at the same time using identical
reagents, with the exception of the streptavidin-en-
zyme/substrate reagents. The dynamic range of the
assays, measured by the ratio of the signal of the 600
μg/l standard to the zero standard (after substraction
10 100
Myeloperoxidase [pg/l]
Fig. 4. Comparison of standard curves from AMPPD, luminol/
peroxide and 4-nitrophenyl phosphate as signal re-
agents. All assays were set up identically on one micro-
titre plate. Only the substrates differed (see table 2). All
reactions took place at ambient temperature
(18-25°C).
- * - LEIA-POD -- + -- LEIA-AP ········· EIA-AP
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of the reagent blank) was 180:1 for the luminol-
peroxidase system, 150:1 for AMPPD and 65:1 for
the 4-nitrophenyl phosphate system. These data were
the optimal values measured 5 minutes after substrate
addition for the luminol/peroxide system, after 30
minutes for the AMPPD system and after 10 minutes
for the 4-nitrophenyl phosphate system.
i) Precision of microutre plate assays
The precision of microtitre plate assays is similar to
that for the polystyrene ball-based assays. This is
clearly shown by comparison of the data in tables 4
and 5.
Tab. 5. Precision data from the microtitre plate assay using
AMPPD — alkaline phosphatase as label
a. Compound precision profile
(Data from duplicate determinations)
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Myeloperoxidase (Calbiochem) [U/l]
Fig. 5. Relationship between commercial myeloperoxidase
preparation (abscissa) and laboratory internal standard
in pathological urine (ordinate). Each point is composed
of results from 8 individual assays. The immunological
reactivity of both preparations is the same over a wide
measuring range. The antibody reacts specifically, as
the urine also contains elastase complexes (110 mg/1)
and lactoferrin (85 mg/1).
• Assay 1 -f Assay 2 *· Assay 3 D Assay 4
χ Assay 5 Ο Assay 6 Δ Assay 7 χ Assay 8
Regression r = 0.999
Intercept = 0 Slope = 120
oratory internal urinary standard. The correlation
data show that an excellent consensus between both
standards was achieved. Mass units were used in
routine assays as an immunoassay does not necessar-
ily reflect enzymic activity.
Only irradiated microtitre plates were suitable, the
capacity of normal plates to adsorb antibody not
being sufficient. Normal plates could be made into
"high-capacity" plates by pretreatment with poly
phenylalanine-lysine/pentan-l,5-dial as described in
the literature (15, 16).
j) Standardisation of the myeoloperoxidase assay
As there are no international reference preparations
for myeloperoxidase, comparison was made between
the laboratory standard, extracted from urine of a
patient with acute renal rejection, and a commercially
available myeloperoxidase preparation (Behring-Cal-
biochem) with declared activity and purity.
The protein content of the commercial preparation
was determined using bovine serum albumin as stand-
ard and the Biorad protein assay based on Coomassie
blue reaction. A value of 120 μg/U was measured.
Figure 5 shows serial dilutions of the commercial
standard from 8 assays as measured against the lab-
k) Comparison of results from the direct labelled assay
using polystyrene balls with those from the
AMPPD I alkaline phosphatase microtitre plate as-
say
One hundred and sixty plasma samples were measured
simultaneously in 8 consecutive assays using ABEN
or AMPPD as luminogen. Myeloperoxidase concen-
trations ranged from 72 to 1310 μg/l. The Spearman
rank correlation coefficient was 0.984, the slopes of
the regression lines y = a + bx and χ = a + by, being
0.972 and 1.018 respectively. This data confirmed that
both assays measured the same concentrations within
statistically acceptable limits.
I) Final discussion points
We demonstrate not only new assay systems for the
non-radioisotopic determination of myeloperoxidase
in body fluids, but also support the claims made over
a decade ago (17) that if an assay is well designed,
the choice of label is often of secondary importance.
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The assays based on enhanced luminescence allow
one of the basic criticisms and drawbacks of chemil-
uminescence-based measurements — namely the
"one-off measurement — to be overcome.
The use of a luminescent detection system in combi-
nation with an enzyme label allows the Beer-Lambert
law for colorimetric measurements to be overcome.
The low, non-specific signal of AMPPD reduces the
lower detection limit, at the same time increasing the
measuring range of the assay.
The stability of reagents is excellent, for example the
streptavidin-alkaline phosphatase used in this study
was kept in solution for over 2 years stored at 4 °C.
ABEN-labelled antibodies have shelf lives of over 5
years, when stored under —27 °C.
The use of microtitre plate luminometers, combined
with assays which need no reagent injection step in
the instrument, make this system attractive and re-
duces the costs of instrumentation. It also allows those
who aready possess such a luminometer, for example,
the Amerlite system, to develop and implement their
own assays, either using peroxidase or alkaline phos-
phatase as labels.
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